Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor alisporivir (Debio 025)
L Softic, R Brillet, F Berry, N Ahnou… - Antimicrobial agents …, 2020 - Am Soc Microbiol
L Softic, R Brillet, F Berry, N Ahnou, Q Nevers, M Morin-Dewaele, S Hamadat, P Bruscella…
Antimicrobial agents and chemotherapy, 2020•Am Soc MicrobiolCyclophilins play a key role in the life cycle of coronaviruses. Alisporivir (Debio 025) is a
nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition
properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner
in Vero E6 cells, with a 50% effective concentration (EC50) of 0.46±0.04 μM. Alisporivir
inhibited a postentry step of the SARS-CoV-2 life cycle. These results justify rapidly
conducting a proof-of-concept phase 2 trial with alisporivir in patients with SARS-CoV-2 …
nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition
properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner
in Vero E6 cells, with a 50% effective concentration (EC50) of 0.46±0.04 μM. Alisporivir
inhibited a postentry step of the SARS-CoV-2 life cycle. These results justify rapidly
conducting a proof-of-concept phase 2 trial with alisporivir in patients with SARS-CoV-2 …
Abstract
Cyclophilins play a key role in the life cycle of coronaviruses. Alisporivir (Debio 025) is a nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in Vero E6 cells, with a 50% effective concentration (EC50) of 0.46 ± 0.04 μM. Alisporivir inhibited a postentry step of the SARS-CoV-2 life cycle. These results justify rapidly conducting a proof-of-concept phase 2 trial with alisporivir in patients with SARS-CoV-2 infection.
American Society for Microbiology